MA50255A - Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) - Google Patents
Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)Info
- Publication number
- MA50255A MA50255A MA050255A MA50255A MA50255A MA 50255 A MA50255 A MA 50255A MA 050255 A MA050255 A MA 050255A MA 50255 A MA50255 A MA 50255A MA 50255 A MA50255 A MA 50255A
- Authority
- MA
- Morocco
- Prior art keywords
- nkg2d
- cll
- lectin
- molecule
- binding proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50255A true MA50255A (fr) | 2021-05-26 |
Family
ID=65723086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050255A MA50255A (fr) | 2017-09-14 | 2018-09-13 | Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (fr) |
| EP (1) | EP3681532A4 (fr) |
| JP (2) | JP2020534269A (fr) |
| KR (1) | KR20200051789A (fr) |
| CN (1) | CN111432832A (fr) |
| AU (1) | AU2018331412A1 (fr) |
| BR (1) | BR112020005078A2 (fr) |
| CA (1) | CA3075857A1 (fr) |
| EA (1) | EA202090718A1 (fr) |
| IL (1) | IL273206A (fr) |
| MA (1) | MA50255A (fr) |
| MX (1) | MX2020002880A (fr) |
| SG (1) | SG11202002298PA (fr) |
| WO (1) | WO2019055677A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (fr) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Protéines se liant à her2, nkg2d et cd16 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (fr) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant le recepteur nkg2d |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EP3765516A2 (fr) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
| WO2020010250A2 (fr) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
| CA3108427A1 (fr) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteines de liaison multi-specifiques se liant a bcma, nkg2d et cd16, et methodes d'utilisation |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| WO2021138474A2 (fr) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
| WO2021226163A2 (fr) * | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Anticorps ciblant clec12a et leur utilisation |
| AU2021268340A1 (en) * | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (fr) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur |
| PE20241789A1 (es) | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| WO2007002905A1 (fr) * | 2005-06-29 | 2007-01-04 | University Of Miami | Proteine de fusion anticorps-ligand de cellule immunitaire pour le traitement du cancer |
| WO2009077483A1 (fr) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Anticorps humains anti-nkg2d et leurs utilisations |
| EP2014680A1 (fr) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne |
| ES2550384T3 (es) * | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| EP3851457A1 (fr) * | 2016-01-21 | 2021-07-21 | Novartis AG | Molécules multispécifiques ciblant cll-1 |
| MX2019010156A (es) * | 2017-02-27 | 2020-01-09 | Dragonfly Therapeutics Inc | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. |
-
2018
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/fr not_active Ceased
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/fr active Pending
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 CA CA3075857A patent/CA3075857A1/fr active Pending
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024099539A (ja) | 2024-07-25 |
| KR20200051789A (ko) | 2020-05-13 |
| EP3681532A4 (fr) | 2021-09-01 |
| CA3075857A1 (fr) | 2019-03-21 |
| IL273206A (en) | 2020-04-30 |
| EP3681532A1 (fr) | 2020-07-22 |
| MX2020002880A (es) | 2020-10-01 |
| AU2018331412A1 (en) | 2020-03-26 |
| JP2020534269A (ja) | 2020-11-26 |
| SG11202002298PA (en) | 2020-04-29 |
| WO2019055677A1 (fr) | 2019-03-21 |
| BR112020005078A2 (pt) | 2020-10-13 |
| CN111432832A (zh) | 2020-07-17 |
| US20200277384A1 (en) | 2020-09-03 |
| EA202090718A1 (ru) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47508A (fr) | Protéines de liaison à cd33, nkg2d et cd16 | |
| IL268567A (en) | Proteins binding bcma, nkg2d and cd16 | |
| IL268755A (en) | Proteins binding her2, nkg2d and cd16 | |
| EP3679071A4 (fr) | Protéines de liaison à nkg2d, cd16 et un antigène associé à une tumeur | |
| EP3833385A4 (fr) | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur | |
| EP3641762A4 (fr) | Dégrons et dégronimères à liaison n/o pour la dégradation de protéines | |
| IL280512A (en) | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use | |
| IL280673A (en) | Proteins binding nkg2d, cd16 and a tumor-associated antigen | |
| IL273206A (en) | Proteins that bind NKG2D, CD16, and C-type lectin-like molecule (CLL-1) | |
| EP3795595A4 (fr) | Protéine de fusion se liant à la protéine cd47 et utilisation associée | |
| IL272374A (en) | Proteins binding nkg2d, cd16 and flt3 | |
| IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
| EP3717505A4 (fr) | Protéines de liaison à l'adn modifiées | |
| EP3655432A4 (fr) | Protéines de liaison 1 | |
| PT3715367T (pt) | Proteína de fusão compreendendo proteína il-2 e proteína cd80, e sua utilização | |
| EP3635013A4 (fr) | Protéines de liaison à la nectine-4 et leurs procédés d'utilisation | |
| IL270803A (en) | A protein binding nkg2d, cd16 and a tumor-associated antigen | |
| MA51291A (fr) | Protéines de fusion il-2 fc modifiées | |
| EP3352760A4 (fr) | Polypeptides de liaison à cd3 | |
| EP3630181A4 (fr) | Protéine de liaison nkg2d, cd16 et antigène associé à une tumeur | |
| IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf | |
| EP3790585A4 (fr) | Protéine de liaison au nkg2d, au cd16 et à un antigène associé à une tumeur | |
| EP3874905A4 (fr) | Configurations de canaux logiques et de ressources de liaison latérale | |
| IL268768A (en) | Proteins binding gd2, nkg2d and cd16 |